Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced an upcoming presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic (RDT) targeting DLL3 for Small Cell Lung Cancer, at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany, October 19-23, 2024. The presentation, titled "Preclinical Assessment of Lead-212 (²¹²Pb) Radio-DARPin Therapeutic (RDT) Targeting Delta-like Ligand 3 (DLL3) in Small Cell Lung Cancer (SCLC)," will be held on October 22, 2024.
MP0712, co-developed with Orano Med, is Molecular Partners' first RDT candidate. It shows low kidney accumulation and high tumor uptake in preclinical models, leading to strong tumor growth inhibition with a good safety profile in vivo. DLL3 is expressed in >85% of SCLC tumors and other aggressive neuroendocrine tumors, making it a priority target for radiopharmaceutical therapy.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) ha annunciato una prossima presentazione su MP0712, un terapeutico Radio-DARPin etichettato con ²¹²Pb (RDT) che mira a DLL3 per il Cancro Polmonare a Piccole Cellule, al Congresso della Associazione Europea di Medicina Nucleare (EANM) a Amburgo, Germania, dal 19 al 23 ottobre 2024. La presentazione, intitolata "Valutazione Preclinica del Terapeutico Radio-DARPin (RDT) a Piombo-212 (²¹²Pb) che Mira al Ligando Delta-like 3 (DLL3) nel Cancro Polmonare a Piccole Cellule (SCLC)," si terrà il 22 ottobre 2024.
MP0712, co-sviluppato con Orano Med, è il primo candidato RDT di Molecular Partners. Mostra bassa accumulo renale e alta assunzione tumorale in modelli preclinici, portando a una forte inibizione della crescita tumorale con un buon profilo di sicurezza in vivo. DLL3 è espresso in oltre l'85% dei tumori SCLC e in altri tumori neuroendocrini aggressivi, rendendolo un obiettivo prioritario per la terapia radiogenuina.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) anunció una próxima presentación sobre MP0712, un terapéutico Radio-DARPin etiquetado con ²¹²Pb (RDT) que se dirige a DLL3 para el Cáncer de Pulmón de Células Pequeñas, en el Congreso de la Asociación Europea de Medicina Nuclear (EANM) en Hamburgo, Alemania, del 19 al 23 de octubre de 2024. La presentación, titulada "Evaluación Preclínica del Terapéutico Radio-DARPin (RDT) con Plomo-212 (²¹²Pb) que Apunta al Ligando Delta-like 3 (DLL3) en el Cáncer de Pulmón de Células Pequeñas (SCLC)," se llevará a cabo el 22 de octubre de 2024.
MP0712, co-desarrollado con Orano Med, es el primer candidato RDT de Molecular Partners. Muestra bajo acumulación renal y alta captación tumoral en modelos preclínicos, lo que conduce a una fuerte inhibición del crecimiento tumoral con un buen perfil de seguridad in vivo. DLL3 se expresa en más del 85% de los tumores SCLC y otros tumores neuroendocrinos agresivos, lo que lo convierte en un objetivo prioritario para la terapia radiofarmacéutica.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN)은 2024년 10월 19일부터 23일까지 독일 함부르크에서 열리는 유럽 핵의학 협회(EANM) 학회에서 DLL3을 목표로 하는 ²¹²Pb 라벨의 Radio-DARPin 치료제 MP0712에 대한 향후 발표를 예정하고 있다고 발표했습니다. 발표 제목은 "소세포 폐암(SCLC)에서 델타-유사 리간드 3(DLL3)를 겨냥한 리드-212(²¹²Pb) Radio-DARPin 치료제(RDT)의 전임상 평가"이며, 2024년 10월 22일에 열립니다.
MP0712는 Orano Med와 공동 개발한 Molecular Partners의 첫 번째 RDT 후보입니다. 이 약물은 전임상 모델에서 신장 축적이 낮고 종양 흡수가 높습니다, 이는 인체 내에서 강력한 종양 성장 억제와 좋은 안전성 프로파일로 이어집니다. DLL3는 SCLC 종양의 >85% 및 다른 공격적인 신경내분비 종양에서 발현되어 방사성 의약품 치료의 우선 목표가 됩니다.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) a annoncé une prochaine présentation sur MP0712, un thérapeutique Radio-DARPin marqué au ²¹²Pb (RDT) ciblant DLL3 pour le Cancer du Poumon à Petites Cellules, lors du Congrès de l'Association Européenne de Médecine Nucléaire (EANM) à Hambourg, en Allemagne, du 19 au 23 octobre 2024. La présentation, intitulée "Évaluation Préclinique du Thérapeutique Radio-DARPin (RDT) à Plomb-212 (²¹²Pb) Ciblant le Ligand Delta-like 3 (DLL3) dans le Cancer du Poumon à Petites Cellules (SCLC)," se déroulera le 22 octobre 2024.
MP0712, co-développé avec Orano Med, est le premier candidat RDT de Molecular Partners. Il montre une faible accumulation rénale et une forte captation tumorale dans des modèles précliniques, entraînant une forte inhibition de la croissance tumorale avec un bon profil de sécurité in vivo. DLL3 est exprimé dans plus de 85 % des tumeurs SCLC et dans d'autres tumeurs neuroendocrines agressives, ce qui en fait une cible prioritaire pour la thérapie radiopharmaceutique.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) hat eine bevorstehende Präsentation über MP0712, ein mit ²¹²Pb gekennzeichnetes Radio-DARPin-Therapeutikum (RDT), das auf DLL3 für Kleinzelliges Lungenkarzinom abzielt, auf dem Kongress der Europäischen Nuklearmedizinervereinigung (EANM) in Hamburg, Deutschland, vom 19. bis 23. Oktober 2024 angekündigt. Die Präsentation mit dem Titel "Präklinische Bewertung des Blei-212 (²¹²Pb) Radio-DARPin-Therapeutikums (RDT), das Delta-like Ligand 3 (DLL3) im Kleinzelligen Lungenkarzinom (SCLC) anvisiert," findet am 22. Oktober 2024 statt.
MP0712, das gemeinsam mit Orano Med entwickelt wurde, ist der erste RDT-Kandidat von Molecular Partners. In präklinischen Modellen zeigt es niedrige Nierenakkumulation und hohe Tumoraufnahme, was zu starker Hemmung des Tumorwachstums mit einem guten Sicherheitsprofil in vivo führt. DLL3 wird in über 85% der SCLC-Tumoren und anderen aggressiven neuroendokrinen Tumoren exprimiert, was es zu einem vorrangigen Ziel für die radiopharmazeutische Therapie macht.
- MP0712 shows low kidney accumulation and high tumor uptake in preclinical models
- MP0712 demonstrates strong tumor growth inhibition with a good safety profile in vivo
- DLL3 is expressed in >85% of SCLC tumors, making it a promising target
- Presentation at EANM 2024 indicates scientific recognition and potential interest in MP0712
- None.
Insights
The presentation of MP0712, a 212Pb-labeled Radio-DARPin Therapeutic (RDT) targeting DLL3 for Small Cell Lung Cancer (SCLC), at EANM 2024 is a significant development for Molecular Partners. This preclinical data showcases several promising aspects:
- Low kidney accumulation and high tumor uptake in preclinical models
- Strong tumor growth inhibition with a good safety profile in vivo
- Potential efficacy in SCLC, where DLL3 is expressed in
85% of cases
The RDT platform's unique approach, combining DARPin's specificity with radioactive payloads, could represent a novel treatment modality for solid tumors. However, it's important to note that this is still in the preclinical stage and success in human trials is not guaranteed. The collaboration with Orano Med adds credibility to the project, potentially accelerating development. While this news is promising for Molecular Partners' pipeline, investors should remain cautious as clinical trials and regulatory approvals are still far off.
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models
MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like ligand 3 (DLL3) co-developed with Orano Med, at the European Assocation of Nuclear Medicine (EANM) Congress which runs October 19-23, 2024 in Hamburg, Germany.
The presentation details are as follows:
Title: Preclinical Assessment of Lead-212 (212Pb) Radio-DARPin Therapeutic (RDT)
Targeting Delta-like Ligand 3 (DLL3) in Small Cell Lung Cancer (SCLC)
Presentation Number: OP-535
Session Number: 1204
Session Title: M2M Track – Top Rated Oral Presentation (TROP) Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation
Session Timing & Location: October 22, 2024; 8:00-9:30 a.m. CET, Hall X1–X4
Presentation Timing: October 22, 2024; 9:20-9:30 a.m. CET
The presentation will be made available on Molecular Partners’ website after the conference.
Molecular Partners is developing a unique and innovative RDT platform for targeted delivery of radioactive payloads to solid tumors. Due to their small size, high specificity and affinity, DARPins are well-suited as vector for efficient delivery of therapeutic radionuclides. In June 2024, Molecular Partners, together with Targeted Alpha Therapy pioneers Orano Med, announced MP0712, a 212Pb-labeled DLL3-targeting radiopharmaceutical as their first co-developed RDT candidate.
DLL3 is a priority target for radiopharmaceutical therapy thanks to its abundant expression in tumors of patients with SCLC (>
At EANM 2024, Molecular Partners will present their preclinical results supporting MP0712 as a promising treatment candidate for SCLC, with an attractive biodistribution profile, potent antitumor activity and a good safety profile.
About DARPin Therapeutics
DARPin (Designed Ankyrin Repeat Protein) therapeutics are a new class of custom-built protein drugs based on natural binding proteins that open new dimensions of multi-functionality and multi-target specificity in drug design. The flexible architecture, intrinsic potential for high affinity and specificity, small size and high stability of DARPins offer benefits to drug design over other currently available protein-based therapeutics. DARPin candidates can be radically simple, with a single DARPin unit acting as the delivery vector to a specific target; or multispecific, with the possibility of engaging more than five targets, and combining multiple and conditional functionalities in a unique DARPin drug candidate. The DARPin platform is designed to be a rapid and cost-effective drug discovery engine, producing drug candidates with optimized properties and high production yields. DARPin therapeutics have been clinically validated across several therapeutic areas and developed through to the registrational stage.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter/X @MolecularPrtnrs
About Orano Med SAS
Orano Med is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). The company develops several treatments using 212Pb combined with various targeting agents. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe. For more information, please visit: www.oranomed.com.
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2024 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential that Molecular Partners’ product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may impact Molecular Partners’ financial and business projections and guidance; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners’ Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with Securities and Exchange Commission (SEC) on March 14, 2024 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is MP0712 and what is it targeting?
When and where will Molecular Partners (MOLN) present their findings on MP0712?
What are the key preclinical results for MP0712 mentioned in the press release?
Why is DLL3 considered a priority target for radiopharmaceutical therapy in SCLC?
